Company Insights

ICMB customer relationships

Explore interactive graphBrowse insights index

ICMB customers relationship map

Investcorp Credit Management BDC (ICMB): portfolio counterparties and what they reveal

Investcorp Credit Management BDC (ICMB) operates as a middle‑market private credit vehicle that originates and holds first‑ and second‑lien loans, unitranche facilities and related equity securities; it monetizes through net investment income (interest, accretion, PIK and structuring fees), realized gains on exits and fees for managerial assistance. For investors, the recent disclosure set underscores a portfolio composed of typical middle‑market credits, a mix of active financings and realizations, and a small number of larger fair‑value exposures that drive headline risk. For a rapid, structured assessment of counterparty exposure and operational posture, read on. (Learn more at https://nullexposure.com/.)

Quick read: the portfolio relationships ICMB named

Below are every counterparty referenced in the available transcripts and news captures, each summarized in one or two plain‑English sentences with the source for verification.

  • 4L Technologies — ICMB disclosed both a preferred‑equity support earlier and a realized first‑lien term loan position following a refinancing during Q4 2025. Source: ICMB Q4 2025 earnings call transcript (March 2026).

  • RESA Power — ICMB reported the realization of its equity stake in RESA Power during the quarter. Source: ICMB Q4 2025 earnings call transcript (March 2026).

  • American Auto Auction (XLerate) — ICMB participated in the refinancing of American Auto Auction (XLerate), described as the second‑largest player in the wholesale used‑car auction market. Source: ICMB Q4 2025 earnings call (March 2026).

  • Asurion — Listed among portfolio investments alongside Integrity Marketing and Alphia, indicating a themed exposure to service‑oriented, scale businesses. Source: ICMB Q4 2025 earnings call (March 2026).

  • Integrity Marketing — Noted as an investment on ICMB’s list of significant portfolio companies, reflecting exposure to insurance distribution/marketing assets. Source: ICMB Q4 2025 earnings call (March 2026).

  • Max U.S. Bidco (Alphia) — Referred to by name as “Max U.S. Bidco, also known as Alphia,” included among ICMB’s sizable investments. Source: ICMB Q4 2025 earnings call (March 2026).

  • Easy Way — ICMB placed Easy Way’s term loan on non‑accrual, a development the company cited as a driver of sequential NII decline. Source: Investing.com transcript of ICMB earnings call (FY2026).

  • LABL, Inc. — ICMB disclosed the full realization of a term‑loan investment in LABL during FY2026. Source: Investing.com earnings summary (FY2026).

  • CareerBuilder — The term loan in CareerBuilder was fully realized during the period; ICMB also holds warrants that are marked at zero in filings. Source: Investing.com / MarketBeat summaries (FY2026).

  • BioPlan / Bioplan — Repeatedly noted as ICMB’s largest single portfolio company by fair value in the period, with disclosed fair‑value figures (~$11–$13.6 million across publications). Source: Investing.com and The Globe and Mail transcripts (FY2026).

  • Axiom Global — ICMB invested $1.5 million in a first‑lien term loan for Axiom Global during the quarter to facilitate a shareholder dividend. Source: Investing.com and MarketBeat earnings summaries (FY2026).

  • Advanced Solutions International — ICMB exited a preferred equity position when the company was recapitalized during the quarter. Source: Investing.com and MarketBeat earnings coverage (FY2026).

  • 1888 (1888 Industrial Services, LLC) — Previously a realized sale (2024) and referred to as a long‑running nonaccrual in historical calls; included in earlier portfolio actions. Source: Company filings and InsiderMonkey transcript (FY2022 / 2024 disclosures).

  • American Teleconference services — Cited in historical non‑accrual commentary alongside 1888; signals legacy workout activity. Source: InsiderMonkey Q3 2022 earnings call transcript (FY2022).

  • PGIE / PGI — Mentioned as “PGI or American Telecom” in historical commentary; ICMB has noted a process of working through this exposure. Source: InsiderMonkey Q3 2022 transcript (FY2022).

  • American Telecom (ATEL) — Referenced as part of the PGI/American Telecom situation in prior disclosures; included in historical non‑accrual discussions. Source: InsiderMonkey historical transcript (FY2022).

  • OCMI (ticker OCMI) / One Call Medical — ICMB reported an investment in the first‑lien term loan of One Call Medical, a tech‑enabled managed‑care provider serving workers’ comp markets. Source: ICMB Q4 2025 earnings call transcript (March 2026).

  • AMCP — ICMB realized a first‑lien term loan position listed on its schedule as AMCP Clean Acquisition Company / PureStar in a refinancing during the quarter. Source: InsiderMonkey Q2 2026 earnings call transcript (FY2025 disclosures).

  • PureStar — Identified in filings as the same entry listed on the schedule for realized first‑lien loans (AMCP/PureStar). Source: InsiderMonkey Q2 2026 earnings call transcript (FY2025 disclosures).

  • Fusion / FSNB — ICMB cited loss of PIK dividend income when a Fusion preferred equity position (FSNB) was placed on non‑accrual; the event reduced income‑earning assets. Source: InsiderMonkey Q2 2026 earnings call transcript (FY2025).

This roster is drawn directly from company remarks and contemporaneous reporting; every company named in the available results is covered above with its immediate disclosure context and public source.

Why the mix matters: operational and business‑model signals

  • Counterparty focus is clearly middle‑market: ICMB repeatedly frames its lending universe as U.S. middle‑market companies (enterprise value < $750m), which drives a hands‑on underwriting and monitoring posture. This is a structural feature: middle‑market loans require bespoke structuring, active covenants and managerial assistance—revenue drivers (origination/structuring fees) and cost drivers (diligence, monitoring). Source: company filings / investment commentary.

  • Contracting posture trends long‑term: Filings indicate multiple multi‑year term loans and deferred amortization structures (first/second lien, unitranche), consistent with a long‑term lender model that accrues origination and OID into interest income. This creates duration and valuation sensitivity in the portfolio. Source: prospectus and offering exhibits referenced in ICMB filings.

  • Role mix expands beyond lender to seller/service provider: ICMB acts as lender and occasional seller (secondary sales and realizations) and provides managerial assistance to portfolio companies—generating fee income but also embedding operational exposure. Source: management commentary and filing language.

  • Geography is primarily North America with global sponsor links: Investment activity focuses on U.S. middle‑market borrowers, while Investcorp affiliation supplies global distribution and capital; this duality creates local credit concentration with global macro sensitivity. Source: company overview and risk disclosures.

  • Dollar‑scale spend bands are mid‑range: Unfunded commitments and disclosed single‑position fair values suggest typical commitment sizes in the $1m–$10m band, aligning with the BDC model of diversified mid‑market lending. Source: consolidated statements and commitment tables.

Key risk and catalyst takeaways for investors

  • Non‑accruals and realized exits drive near‑term NII volatility. Management flagged Easy Way and a Fusion preferred as drivers of sequential NII declines; realizations in CareerBuilder, LABL and Advanced Solutions International altered income and liquidity positioning. Source: Investing.com and MarketBeat earnings summaries (FY2026).

  • Concentration in a handful of larger positions creates headline risk. Management identifies BioPlan as the largest single fair‑value exposure in the period; shifts in those few positions materially move NAV and realized gains/losses. Source: The Globe and Mail / earnings transcripts (FY2026).

  • Active portfolio management is both a strength and a cost. ICMB’s practice of funding dividends, supporting recapitalizations and participating in refinancings (Axiom Global, XLerate, One Call Medical) preserves relationships and yield but increases near‑term cash deployment requirements and professional fees. Source: Q4 2025 earnings call and public reports.

Bottom line and action points

Investcorp Credit Management BDC runs a classic middle‑market BDC playbook—originating structured, typically long‑dated loans and related equity instruments, collecting fees and accruing income, while actively managing workouts and realizations. The company’s named counterparties reflect that strategy: a mix of service businesses, software/tech‑enabled providers and distribution/manufacturing borrowers with position sizes in the low single‑digit millions to low tens of millions. Investors should focus on non‑accrual trends, the valuation of the largest fair‑value positions (BioPlan), and the cadence of realizations and refinancings as the primary near‑term NAV drivers. For ongoing monitoring and deeper counterparty tracking, see our research hub at https://nullexposure.com/.

For any follow‑up analysis — position‑level P&L impact, maturity laddering or covenant density review — contact our coverage team through the site.

Join our Discord